Why I prefer 23-gauge instruments


23-gauge instruments offer numerous advantages over other instruments, such as less irritation, no induction of astigmatism, shorter operation time and lower costs.

So what instrumentation is best for vitreoretinal surgery? A fairly straightforward question on the face of it, but it is, in fact a surprisingly difficult question to answer. I intend to put forward the case for 23-gauge surgery, my preference, and, in order to do this, I first need to explain why I generally prefer transconjunctival vitrectomy to traditional 20-gauge vitrectomy. Finally, I will explain why I use 23-gauge rather than 25-gauge and why I do not perform 20-gauge transconjunctival surgery.

In answer to the first question: Why do I prefer the transconjunctival technique? Briefly, it involves no conjunctival or scleral surgery, so it has no associated Vicryl-related inflammatory reactions and, in most cases, leaves the eye free of irritation. Furthermore, it does not induce astigmatism, the operation time is usually shorter, the surgery cost is lower and there is an almost complete lack of postoperative complaints over a shorter rehabilitation time. For me, however, transconjunctival vitrectomy has other advantages that are at least as, if not more, important. For instance, it leaves much better conditions for additional interventions, whereas after three multiple 20-gauge surgeries, the sclera would be largely destroyed.

Valved cannula makes an impact

Secondly, the cannula decreases the vitreous incarceration. Although this has not yet been proven, I am convinced that it is true for two reasons. Its lumen is smaller and the smaller the lumen the less vitreous can pass through it. Secondly, its length is greater, again allowing less vitreous to escape than would during an open sclerotomy. The cannula, therefore, helps to reduce the risk of postoperative traction retinal detachment. This is particularly applicable if you use a valved cannula rather than a conventional cannula.

Valved cannulas alone are reason enough why I will never return to traditional vitrectomy. The valve system prevents the loss of intraocular fluid when the surgeon switches instruments and the resistance from the valve should also be as low as possible to ensure that the cannula is not inadvertently removed. They allow me to operate as I have always wanted to operate, namely within a closed system, allowing for much quicker and safer surgery.

Minor disadvantages are easily overcome

Although transconjunctival vitrectomy does have tremendous advantages, I also accept its drawbacks, in particular the poorer effectiveness of the instruments, the greater flexibility, and the lack of angled instruments. In order to combat these problems, I use 23-gauge instruments, which are more stable and allow me to work more quickly than I could with 25-gauge instruments. Some may argue that with 25-gauge instruments the sclerotomy can be made perpendicularly, whereas with 23-gauge a tunneled incision must be made. However, this can be achieved so quickly and simply that it does not, in my opinion, represent a real disadvantage. Quite the contrary, the tunneled sclerotomy is beneficial because it results in better closure than can be achieved with a perpendicular 25-gauge sclerotomy.

At the cutting edge

Related Videos
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Giulia Corradetti, MD, discusses her presentation "Functional Microperimetric Correlates of OCT Structures Features in Intermediate AMD"
At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network
Baruch Kuppermann, MD, PhD
At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns."
Ash Abbey, MD, shares 36-month data from the GALE study of pegcetacoplan
© 2024 MJH Life Sciences

All rights reserved.